The ALS Association, which supports research on amyotrophic lateral sclerosis, has awarded a grant to Tiziana Life Sciences to support a clinical trial of intranasal foralumab in 20 patients with ALS at Massachusetts General Hospital, Tiziana said. The amount of the award was not disclosed. According to Tiziana, the trial will use PET imaging to evaluate the effectiveness of the nasal spray in reducing neuroinflammation in ALS patients.
Intranasal foralumab, a human anti-CD3 monoclonal antibody, is currently being evaluated in a Phase 2a trial for the treatment of non-active secondary progressive multiple sclerosis and is being used to treat patients with na-SPMS under an expanded access program. The FDA recently granted Fast Track designation for that indication. An expanded access program for the use of intranasal foralumab in patients with Alzheimers disease has also been approved.
ALS Association Senior VP Kuldip Dave commented, “The Hoffman ALS Clinical Trial Awards Program supports early-stage clinical trials of potential new therapies that hold promise for those living with ALS. With this award, we are pleased to help advance the development of intranasal foralumab for ALS. By funding programs at this early stage, we hope to accelerate the development of therapeutic candidates that can help make ALS a livable disease.”
Tiziana Life Sciences CEO Ivor Elrifi said, “We are honored to receive this prestigious grant from the ALS Association, which underscores the promising potential of our therapeutic platform in addressing the urgent needs of ALS patients. This funding will accelerate our clinical development efforts and bring us closer to potentially transformative treatment options for ALS. Tiziana Life Sciences’ innovative approach targets the underlying mechanisms of ALS with the aim of halting or slowing disease progression. The company’s commitment to rigorous scientific research and patient-centric innovation aligns with the ALS Association’s mission to discover treatments and a cure for ALS, as well as to serve, advocate for, and empower people affected by ALS.”
Read the Tiziana Life Sciences press release.
